Accuracy of <sup>18</sup>F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.

Valkema, Maria J; Noordman, Bo Jan; Wijnhoven, Bas P L; Spaander, Manon C W; Biermann, Katharina; Lagarde, Sjoerd M; Bennink, Roel J; Schreurs, Wendy M J et al. · J Nucl Med · 2019

Where this comes from

Abstract

Our purpose was to prospectively investigate optimal evaluation of qualitative and quantitative <sup>18</sup>F-FDG PET/CT in response evaluations 12-14 wk after neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer patients. <b>Methods:</b> This was a side study of the prospective diagnostic pre-SANO trial. <sup>18</sup>F-FDG PET/CT scans at baseline and at 12-14 wk after nCRT were qualitatively assessed for the presence of tumor. Maximum SUVs normalized for lean body mass (SUL<sub>max</sub>) were measured in all scans. The primary endpoint was the proportion of false-negative patients with tumor regression grade (TRG) 3-4 (>10% vital residual tumor) in qualitative and quantitative analyses. Receiver-operating-characteristic curve analysis for TRG1 versus TRG3-4 using SUL<sub>max</sub>, SUL<sub>max</sub> tumor-to-esophagus ratio, and Δ%SUL<sub>max</sub> was performed to define optimal cutoffs. Secondary endpoints were sensitivity, specificity, negative predictive value, and positive predictive value for TRG1 versus TRG2-4. <b>Results:</b> In total, 129 of 219 patients were analyzed. Qualitative <sup>18</sup>F-FDG PET/CT was unable to detect TRG3-4 in 15% of patients. Sensitivity, specificity, negative predictive value, and positive predictive value in qualitative analysis for detecting TRG1 versus TRG2-4 was 80%, 37%, 42%, and 77%, respectively. In 18 of 190 patients (10%) with follow-up scans after nCRT, <sup>18</sup>F-FDG PET/CT identified new interval metastases. Quantitative parameters did not detect TRG3-4 tumor in 27%-61% of patients. The optimal cutoff for detecting TRG1 versus TRG2-4 was a post-nCRT SUL<sub>max</sub> of 2.93 (area under receiver-operating-characteristic curve, 0.70). <b>Conclusion:</b> Qualitative and quantitative analyses of <sup>18</sup>F-FDG PET/CT are unable to accurately detect TRG3-4 and to discriminate substantial residual disease from benign inflammation-induced <sup>18</sup>F-FDG uptake after nCRT. However, <sup>18</sup>F-FDG PET/CT is useful for the detection of interval metastases and might become useful in an active surveillance strategy with serial <sup>18</sup>F-FDG PET/CT scanning.

Medical subject headings